Newcastle University

Qualifications

PhD, Newcastle University, (1999)
FIMLS(in clinical chemistry),Newcastle Polytechnic (1988)
BSc Hons (Biochemistry),Warwick University (1983)

Previous Positions

1998-2002 Research Associate, LRF Molecular Pharmacology Specialist Programme, University of Newcastle upon Tyne
1990-98: Junior Research Associate, Depts Haematology and Child Health, University of Newcastle upon Tyne
1983-90: MLSO, Royal Victoria Infirmary, Newcastle upon Tyne

Memberships

Bristish Association for Cancer Research
American Association for Cancer Research (Active member)

Research Interests

drug metabolism (HPLC)
tissue culture
cytotoxixcity studies (apoptosis, clonogenic and cytotoxicity assays)
Protein studies (western blotting,immunocytochemistry, immunoprecipitation)

Other Expertise

protein purification
PCR
cloning

Current Work

Factors influencing the metabolism and efficacy of thiopurine drugs
Cell cycle de-regulation in acute lymphoblastic leukemia

Future Research

Role of cell cycle de-regulation in acute lymphoblastic leukemaemia including:
gene silencing by methylation
ubiquitylation
translational dysfunction
aberrant cell signalling and mislocalisation of cell cycle regulators
potential use of cdk inhibitors as a novel therapy

Research Roles

HPLC training
Laboratory radiation protection officer
Supervision of students

Postgraduate Supervision

any areas in main expertise/research interests section above

Funding

SNP Chip analysis in ALL. Hall A.G., Irving, J.A.E, Hogarth, L.A. 2005 LRF

Role of p21 inactivation in acute lymphoblastic leukaemia. L.Hogarth, S.Coulthard, A.G. Hall 1st Oct2003-1st Oct 2006 (PhD Studentship) TLFR

Optimisation of Chemotherapy in Childhood in Childhood Acute Lymphoblastic Leukaemia (£1,391,876):Hall A.G., Coulthard, S.A., Hogarth, L.A., Irvine, J.A.E., 1st April 2002-31st March 2007 Leukaemia Research Fund.

The Role of Thiopurine Methyltransferase in determining Sensitivity to Thiopurine Drugs: Hall, A.G., Coulthard, S.A., Hogarth, L.A., Pearson, A.D.P. (Clinical Training Fellowship) 1st June 2001-31st May 2002 Leukaemia Research Fund

• Esfandiari A, Shoaib M, Hogarth L, Panlilio L. Establishing pavlovian to instrumental transfer (PIT) with intravenous nicotine and sucrose in rats. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
• Coulthard SA, Redfern CPF, Vikingsson S, Lindqvist-Appell M, Skoglund K, Jakobsen-Falk I, Hall AG, Taylor GA, Hogarth LA. Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. Molecular Cancer Therapeutics 2011, 10(3), 495-504.
• Davies C, Hogarth LA, Dietrich PA, Bachmann PS, Mackenzie KL, Hall AG, Lock RB. p53-independent Epigenetic Repression of the p21(WAF1) Gene in T-cell Acute Lymphoblastic Leukemia. Journal of Biological Chemistry 2011, 286(43), 37639-37650.
• Irving JAE, Bloodworth LC, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Research 2005, 65(8), 3053-3058.
• Coulthard SA, Hogarth LA. The thiopurines: An update. Investigational New Drugs 2005. , 23(6), 523-532.
• Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. In: Joint 11th International and 9th European Symposium on Purines and Pyrimidines. 2004, Man Egmond Aan Zee, Netherlands: Nucleosides, Nucleotides and Nucleic Acids: Taylor & Francis Inc..
• Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 2002, 62(1), 102-109.
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999, 93(8), 2671-2678.
• Hogarth LA, English M, Price L, Wyllie R, Pearson ADJ, Hall AG. The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine. Cancer Chemotherapy and Pharmacology 1996, 37(5), 479-485.